Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2025-12-26 @ 12:24 AM
NCT ID:
NCT02805660
Group ID:
EG001
Title:
Phase 1: Dose Escalation - 70 mg
Description:
The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this phase.
Mocetinostat: Participants received mocetinostat three times weekly as an oral capsule.
Durvalumab - 1500 mg: Participants received durvalumab as an intravenous infusion every 4 weeks.
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
1
Serious Number At Risk:
4
Other Number Affected:
4
Other Number At Risk:
4
Study:
NCT02805660
Results Section:
NCT02805660
Adverse Events Module:
NCT02805660